human PC3 cells |
Function assay |
100 μM |
48 h |
Inhibition of actin based pseudopodia formation in androgen-dependent human PC3 cells at 100 uM after 48 hrs by DAPI staining based fluorescence microscopy assay |
22672984 |
human PC3 cells |
Function assay |
0.1-1 μM |
|
Agonist activity at androgen receptor W741C mutant expressed in human PC3 cells assessed as stimulation of receptor transactivation at 0.1 to 1 uM by luciferase reporter gene assay |
22175694 |
HEK293 cells |
Function assay |
|
3 h |
Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, IC50=54 nM |
22391033 |
CHO-K1 cells |
Function assay |
|
2 h |
Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting, IC50=0.2 μM |
20381361 |
human LNCAP cells |
Proliferation assay |
|
3 days |
Antiproliferative activity against human LNCAP cells after 3 days, IC50=0.7327 μM |
26046313 |
human 22Rv1 cells |
Function assay |
|
3 days |
Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay, IC50=4.6 μM |
24900588 |
human LNCAP cells |
Cytotoxic assay |
|
2 days |
Cytotoxicity against human LNCAP cells assessed as cell viability after 2 days by cell counting method, IC50=23.79 μM |
23727044 |
human DU145 cells |
Cytotoxic assay |
|
72 h |
Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay, IC50=18 μM |
SANGER |
human MDA-MB-453 cells |
Function assay |
|
|
Displacement of [3H]R1881 from AR in human MDA-MB-453 cells, EC50=31 nM |
23713567 |
LNCaP cells |
Function assay |
|
|
Inhibition of [3H]-DHT binding to T877A androgen receptor of LNCaP cells, Ki=35 nM |
15603960 |
Freestyle293F cells |
Function assay |
|
|
Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, IC50=0.054 μM |
23199477 |
MDA453 cells |
Function assay |
|
|
Displacement of [3H]DHT from human androgen receptor in MDA453 cells, Ki=64 nM |
18291644 |
human MDA-MB-453 cells |
Function assay |
|
|
Displacement of [3H]DHT from AR in human MDA-MB-453 cells, IC50=64 nM |
20584610 |
COS1 cells |
Function assay |
|
|
Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, IC50=0.0869 μM |
25646649 |
HeLa cells |
Function assay |
|
|
Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, IC50=0.14 μM |
17804229 |
CV1 cells |
Function assay |
|
|
Binding affinity to human androgen receptor expressed in CV1 cells, Ki=0.151 μM |
17257838 |
monkey COS7 cells |
Function assay |
|
|
Binding affinity to human androgen receptor expressed in monkey COS7 cells by whole cell binding assay, Ki=0.151 μM |
18442912 |
COS7 cells |
Function assay |
|
|
Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay, EC50=0.18 μM |
22094279 |
human PC3 cells |
Function assay |
|
|
Displacement of [3H]R1881 from androgen receptor in human PC3 cells, EC50=4.3 μM |
25591066 |
human HT-3 cell |
Growth inhibition assay |
|
|
Inhibition of human HT-3 cell growth in a cell viability assay, IC50=0.73134 μM |
SANGER |
human CCF-STTG1 cell |
Growth inhibition assay |
|
|
Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50=4.92929 μM |
SANGER |
human SCC-25 cell |
Growth inhibition assay |
|
|
Inhibition of human SCC-25 cell growth in a cell viability assay, IC50=6.08656 μM |
SANGER |
human MKN45 cell |
Growth inhibition assay |
|
|
Inhibition of human MKN45 cell growth in a cell viability assay, IC50=6.9605 μM |
SANGER |
human ES5 cell |
Growth inhibition assay |
|
|
Inhibition of human ES5 cell growth in a cell viability assay, IC50=8.61154 μM |
SANGER |
human SK-MEL-3 cell |
Growth inhibition assay |
|
|
Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=10.0964 μM |
SANGER |
human PC-3 cell |
Growth inhibition assay |
|
|
Inhibition of human PC-3 cell growth in a cell viability assay, IC50=10.2791 μM |
SANGER |
human NOS-1 cell |
Growth inhibition assay |
|
|
Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=11.2917 μM |
SANGER |
human LB1047-RCC cell |
Growth inhibition assay |
|
|
Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=12.253 μM |
SANGER |
human CAMA-1 cell |
Growth inhibition assay |
|
|
Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50=12.3926 μM |
SANGER |
human SAS cell |
Growth inhibition assay |
|
|
Inhibition of human SAS cell growth in a cell viability assay, IC50=13.3081 μM |
SANGER |
human NCI-H2228 cell |
Growth inhibition assay |
|
|
Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50=13.7531 μM |
SANGER |
human NCI-H187 cell |
Growth inhibition assay |
|
|
Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50=16.6616 μM |
SANGER |
human BFTC-905 cell |
Growth inhibition assay |
|
|
Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=17.4857 μM |
SANGER |
human G-361 cell |
Growth inhibition assay |
|
|
Inhibition of human G-361 cell growth in a cell viability assay, IC50=17.826 μM |
SANGER |
human SW780 cell |
Growth inhibition assay |
|
|
Inhibition of human SW780 cell growth in a cell viability assay |
SANGER |
human BB49-HNC cell |
Growth inhibition assay |
|
|
Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=18.9532 μM |
SANGER |
human KALS-1 cell |
Growth inhibition assay |
|
|
Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=19.6635 μM |
SANGER |
human AU565 cell |
Growth inhibition assay |
|
|
Inhibition of human AU565 cell growth in a cell viability assay, IC50=19.7402 μM |
SANGER |
human NCI-H2087 cell |
Growth inhibition assay |
|
|
Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50=21.0591 μM |
SANGER |
human RVH-421 cell |
Growth inhibition assay |
|
|
Inhibition of human RVH-421 cell growth in a cell viability assay, IC50=21.5795 μM |
SANGER |
human SK-CO-1 cell |
Growth inhibition assay |
|
|
Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50=21.8872 μM |
SANGER |
human KU-19-19 cell |
Growth inhibition assay |
|
|
Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50=22.0242 μM |
SANGER |
human NB6 cell |
Growth inhibition assay |
|
|
Inhibition of human NB6 cell growth in a cell viability assay, IC50=22.9135 μM |
SANGER |
human RO82-W-1 cell |
Growth inhibition assay |
|
|
Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50=23.1318 μM |
SANGER |
human CTB-1 cell |
Growth inhibition assay |
|
|
Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=24.5536 μM |
SANGER |
human SW48 cell |
Growth inhibition assay |
|
|
Inhibition of human SW48 cell growth in a cell viability assay, IC50=24.6546 μM |
SANGER |
human TCCSUP cell |
Growth inhibition assay |
|
|
Inhibition of human TCCSUP cell growth in a cell viability assay, IC50=24.7232 μM |
SANGER |
human DK-MG cell |
Growth inhibition assay |
|
|
Inhibition of human DK-MG cell growth in a cell viability assay, IC50=24.8917 μM |
SANGER |
human ST486 cell |
Growth inhibition assay |
|
|
Inhibition of human ST486 cell growth in a cell viability assay, IC50=25.7464 μM |
SANGER |
human H4 cell |
Growth inhibition assay |
|
|
Inhibition of human H4 cell growth in a cell viability assay, IC50=26.9458 μM |
SANGER |
human SBC-1 cell |
Growth inhibition assay |
|
|
Inhibition of human SBC-1 cell growth in a cell viability assay, IC50=28.3507 μM |
SANGER |
human CAS-1 cell |
Growth inhibition assay |
|
|
Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=28.6294 μM |
SANGER |
human OAW-42 cell |
Growth inhibition assay |
|
|
Inhibition of human OAW-42 cell growth in a cell viability assay, IC50=28.7195 μM |
SANGER |
human HCC1954 cell |
Growth inhibition assay |
|
|
Inhibition of human HCC1954 cell growth in a cell viability assay, IC50=28.7525 μM |
SANGER |
human MDA-MB-453 cell |
Growth inhibition assay |
|
|
Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50=29.907 μM |
SANGER |
human MCF7 cell |
Growth inhibition assay |
|
|
Inhibition of human MCF7 cell growth in a cell viability assay, IC50=39.301 μM |
SANGER |